Dyne’s Duchenne Exon Skipping Oligomer Shows ‘Differentiated’ Clinical Effect

Dyne is eyeing an accelerated approval filing for DYNE-251 in early 2026 that would pit the asset against Sarepta’s Exondys 51 in a patient population amenable to exon 51 skipping.